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Background: Qualitative alterations of lipoproteins underlie the high incidence of atherosclerosis in diabetes. The
objective of this study was to assess the impact of low-density lipoprotein (LDL) subfraction phenotype on the
qualitative characteristics of LDL and high-density lipoprotein (HDL) in patients with type 2 diabetes.
Methods: One hundred twenty two patients with type 2 diabetes in poor glycemic control and 54 healthy subjects
were included in the study. Patients were classified according to their LDL subfraction phenotype. Seventy-seven
patients presented phenotype A whereas 45 had phenotype B. All control subjects showed phenotype A. Several
forms of modified LDL, HDL composition and the activity and distribution of lipoprotein-associated phospholipase
A2 (Lp-PLA2) were analyzed.
Results: Oxidized LDL, glycated LDL and electronegative LDL were increased in both groups of patients compared
with the control group. Patients with phenotype B had increased oxidized LDL and glycated LDL concentration
than patients with phenotype A. HDL composition was abnormal in patients with diabetes, being these
abnormalities more marked in patients with phenotype B. Total Lp-PLA2 activity was higher in phenotype B than in
phenotype A or in control subjects. The distribution of Lp-PLA2 between HDL and apoB-containing lipoproteins
differed in patients with phenotype A and phenotype B, with higher activity associated to apoB-containing
lipoproteins in the latter.
Conclusions: The presence of LDL subfraction phenotype B is associated with increased oxidized LDL, glycated LDL
and Lp-PLA2 activity associated to apoB-containing lipoproteins, as well as with abnormal HDL composition.
Keywords: Low-density lipoprotein, High-density lipoprotein, Lipoprotein-associated phospholipase A2, Modified
LDL, Type 2 diabetes, LDL subfraction phenotypeBackground
Atherosclerosis-related pathologies are the main cause of
mortality and morbidity in type 2 diabetes. Plasma lipid pro-
file, including hypertriglyceridemia, low high-density lipo-
protein (HDL) cholesterol levels and hyperapolipoprotein B,
is frequently abnormal in these subjects and is a cause of the
high prevalence of macrovascular and microvascular com-
plications [1,2]. However, these quantitative abnormalities* Correspondence: jsanchezq@santpau.cat; aperez@santpau.cat
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distribution, and reproduction in any mediumper se cannot explain all the increase in cardiovascular risk
(CVR) in diabetes, and it is currently accepted that alter-
ations in the qualitative properties of low-density lipoprotein
(LDL) and HDL underlie the development of atherosclerosis
[1]. The concurrence of hypertriglyceridemia and low HDL
cholesterol usually promote the formation of small dense
LDL (sdLDL) particles. This set of features, known as dia-
betic dyslipidemia, is partly for environmental reasons but
also has a significant genetic component [3]. The predomin-
ance of sdLDL is known as LDL subfraction phenotype B, in
contrast to phenotype A, which is characterized by large
buoyant LDL particles. Phenotype A is predominant in
normolipemic subjects with low CVR, whereas phenotype Bed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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CVR, including type 2 diabetes [4].
Other pathological features, such as hyperglycemia,
lipoperoxidation and systemic inflammation are exacer-
bated in diabetes. These processes alter the lipoprotein
function [5], favoring the formation of modified forms
of LDL, such as glycosylated LDL (glLDL), oxidized
LDL (oxLDL) and electronegative LDL (LDL(−)). A
common feature shared by glLDL and oxLDL is the in-
creased negative electric charge. LDL(−), therefore, in-
cludes oxLDL and glLDL, but a major fraction of LDL
(−) particles is generated by alternative mechanisms,
such as lipolysis and non-esterified fatty acid (NEFA)-
loading [6]. This heterogeneity adds value to the meas-
urement of LDL(−), which can be considered as a pool
of modified LDL particles in plasma. The proportion of
oxLDL, glLDL and LDL(−) is increased in subjects with
high CVR, including diabetes [7]. These modified LDLs
have a high content of lipid metabolites with high inflam-
matory potential, including lysophospholipids, whose con-
centration is increased in diabetes [8].
Diabetes also alters normal HDL function. The
antiatherogenic properties of HDL, including its key
role in reverse cholesterol transport and its antioxidant
properties, are disturbed in these patients [9]. Both
functions are modulated by changes in the relative compos-
ition of lipids and proteins in HDL, and also by enzymatic
activities associated to HDL, such as paraoxonase 1 (PON1)
and lipoprotein-associated phospholipase A2 ((Lp-PLA2),
also known as platelet-activating factor acetylhydrolase).
PON1 is exclusively bound to HDL and it has been sug-
gested that it has an antioxidant function by deactivating
lipid peroxides [10]. In contrast to PON1, Lp-PLA2 can as-
sociate with HDL, LDL and VLDL. Controversy exists as to
whether Lp-PLA2 has a pro- or anti-inflammatory action. It
has been recently suggested that the relative distribution of
Lp-PLA2 between LDL and HDL determines its pro- or
anti-inflammatory action. According to this assumption, Lp-
PLA2 in HDL is anti-inflammatory whereas Lp-PLA2 asso-
ciated to apoB-containing lipoproteins is pro-inflammatory
[11]. For this reason, the relative distribution of Lp-PLA2,
rather than its total activity, could be a better CVR marker.
In vitro studies have shown that sdLDL is prone to
modification and it is also known that HDL from pa-
tients with type 2 diabetes has an impaired function.
However, to our knowledge, no previous study has
compared diabetic patients with phenotype A and
phenotype B. This would allow specifically assessing
the impact of LDL subfraction phenotype on the distri-
bution of Lp-PLA2 and other qualitative characteris-
tics of HDL and LDL. The aim of the current work was
to quantify modified forms of LDL, to study the com-
position of HDL and to determine the distribution of
Lp-PLA2 in patients with poorly-controlled type 2diabetes who were classified according to their LDL
subfraction phenotype.Methods
Study population
One hundred twenty two consecutive poor controlled type
2 diabetes subjects who attended the outpatient diabetic
clinic during 2007–2008 to optimize glycemic control were
recruited. Previous hypoglycemic treatment consisted of
diet (22%), oral agents (21.1%), insulin plus oral agents
(29.4%) and insulin (27.5%). Regarding hypolipidemic
drugs, 25.4% of patients were treated with statins or statin
plus ezetimibe, 4.1% with fibrate and 2.5% with statin plus
fibrate. Patients with acute or chronic infections, active in-
flammatory diseases or treatment with anti-inflammatory
drugs were excluded. High sensibility C-reactive protein
(hsCRP, Roche Diagnostics) was routinely measured and
subjects with values higher than 20 mg/L were excluded
from the study. Hypertension was defined as subjects with
a systolic blood pressure of ≥140 mm Hg, with a diastolic
blood pressure of ≥90 mm Hg, or those who were receiving
antihypertensive therapy at the time of examination. Cor-
onary Heart Disease (CHD) was defined as documented
diagnosis of CHD, self-reported positive history of CHD
or electrocardiogram (ECG) positive for CHD. Fifty four
normoglycemic and normolipemic healthy subjects were
included as control group. The study was conducted in ac-
cordance with the principles of the Declaration of Helsinki
and was approved by the Hospital Ethics Committee. All
patients and control subjects gave informed consent.Laboratory determinations
Lipid profile, modified LDLs, HDL composition and Lp-
PLA2 activity distribution were determined from plasma
obtained in EDTA-containing Vacutainer tubes. PON1 ac-
tivity was determined from sera obtained in non-additive
Vacutainer tubes. HbA1c was measured by ion-exchange
high-performance liquid chromatography (HPLC; Variant,
Bio-Rad).
Lipid profile included total cholesterol (Roche) and trigly-
ceride (Roche), very-low density lipoprotein (VLDL), LDL
and HDL cholesterol, total non-esterified fatty acids
(NEFA) (Wako), apoB (Roche), apoA-I (Roche) and apoA-
II (Kamiya Biomedical). Cholesterol of lipoprotein fractions
was measured using a direct method to quantify HDL chol-
esterol (HDL-C plus, Roche) or by ultracentrifugation when
the triglyceride concentration was higher than 3 mmol/L,
according to NCEP recommendations [12]. All determina-
tions were performed in a Hitachi 917 autoanalyzer.
LDL size was determined by non-denaturing polyacryl-
amide gradient (2–16%) gel electrophoresis (GGE), as
described [13]. LDL subfraction phenotype B was de-
fined by a predominant LDL diameter lower than 25.5








B (n = 45)
Control group ANOVA
(n = 54) p-value
Age (years) 60 ± 11 56 ± 11 a 56 ± 14 a 0.108
Male (%) 65.9 64.6 57.4 a, b <0.001
BMI (kg/m2) 29.6 ± 6.2 31.1 ± 4 a 25.9 ± 3.6 a, b <0.001
Waist (cm) 104 ± 15 108 ± 13 a 92 ± 11 a, b <0.001
Diabetes duration (years) 12 ± 11 9 ± 8 a -
Insulin use (%) 58 52 a -
Lipid lowering drugs (%) 30 28 -
HbA1c (%) 9.1 ± 2.1 9.6 ± 2.3 a 5.3 ± 0.6 a, b <0.001
Hypertension (%) 1 69.4 68.2 -
Retinopathy (%) 29.6 29.5 -
Albuminuria (%) 24 29.6 a -
Coronary heart disease (%) 2 5.6 15.9 a -
Total cholesterol (mmol/L) 4.78 ± 1.09 5.64 ± 1.53 a 5.00 ± 0.79 b 0.004
Triglycerides (mmol/L) 1.46 ± 0.79 3.89 ± 3.30 a 0.87 ± 0.37 a,b <0.001
VLDLc (mmol/L) 0.65 ± 0.30 1.43 ± 1.12 a 0.40 ± 0.17 a,b <0.001
LDLc (mmol/L) 2.86 ± 0.95 3.10 ± 0.96 a 2.94 ± 0.66 b 0.281
HDLc (mmol/L) 1.28 ± 0.33 1.02 ± 0.27 a 1.64 ± 0.37 a,b <0.001
NEFA (mmol/L) 0.64 ± 0.29 0.90 ± 0.48 0.41 ± 0.19 a,b <0.001
apoB (g/L) 0.93 ± 0.32 1.09 ± 0.28 a 0.80 ± 0.19 a,b <0.001
apoA-I (g/L) 1.46 ± 0.24 1.37 ± 0.25 a 1.57 ± 0.31 a,b 0.001
apoA-II (g/L) 0.33 ± 0.07 0.34 ± 0.06 0.35 ± 0.05 0.081
LDL size (nm) 26.0 ± 0.4 25.0 ± 0.4 a 26.3 ± 0.1 b <0.001
a, P < 0.05 vs phenotype A patients; b, P < 0.05 vs phenotype B patients. 1 Hypertension was defined as a systolic blood pressure of ≥140 mm Hg, a diastolic blood
pressure of ≥90 mm Hg or those who were receiving antihypertensive therapy at the time of examination. 2 Coronary Heart Disease (CHD) was defined as
documented diagnosis of CHD, self-reported positive history of CHD or ECG positive for CHD.
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higher than 25.5 nm.
oxLDL (Mercodia) and glLDL (Exocell/Glycacor) were
quantified by commercial ELISA. For LDL(−) quantifica-
tion, total LDL was previously isolated by sequential ultra-
centrifugation (density range 1.019-1.050 g/mL). LDL(−)
proportion was determined from total LDL by anion-
exchange chromatography in a MonoQ HR 5/5 column
(GE Healthcare) using a NaCl stepwise gradient [14].
HDL was isolated by sequential ultracentrifugation
(density range 1.063-1.210 g/mL), using KBr gradients.
All steps were performed at 4°C and all KBr solutions
contained 1 mmol/L EDTA and 2 μmol/L BHT to pre-
vent lipoperoxidation during isolation procedures. HDL
composition was determined by measuring the content
of cholesterol (Roche), triglyceride (Roche), phospholipid
(Wako), NEFA (Wako), apoA-I (Roche) and apoA-II
(Kamiya), in a Hitachi 917 autoanalyzer.
PON-1 activity in serum was measured using phenyl-
acetate as substrate, as described [15]. Lp-PLA2 activity
was measured using 2-thio-PAF (Cayman) as substrate,according to the manufacturer’s instructions [16]. To de-
termine the distribution of Lp-PLA2 between lipoprotein
fractions, apoB-containing lipoproteins were precipitated
from serum using dextran sulfate, as described [17].
Briefly, 200 μL of serum were mixed with 50 μL of dex-
tran sulfate reagent, incubated for 5 min at room
temperature, and centrifuged for 10 min at 10,000 g. The
supernatant (depleted of apoB-containing lipoproteins)
was collected and assayed for HDL-associated Lp-PLA2
activity.
Statistical analysis
Statistical analysis was performed using SPSS 19 (SPSS Inc).
Before statistical analysis, normal distribution and homogen-
eity of the variances were tested using Kolmogorov-Smirnov
and Levène tests, respectively. Data that were not normally
distributed were logarithmically transformed before analysis.
Analysis of variables was performed by one-way analysis of
variance (ANOVA). ANCOVA test was used to assess if the
differences seen in ANOVA persisted after adjustment for
triglycerides and HbA1c. Differences between two groups








B (n = 45)
Control group ANOVA
(n = 54) p-value
Modified LDL
Oxidized LDL (U/L) 61.4 ± 20.0 78.6 ± 26.7 a 51.2 ± 19.3 a,b 0.005
Glycated LDL (mg/dL) 2.17 ± 0.94 2.77 ± 1.41 a 1.85 ± 0.73 a,b 0.030
LDL(−) (%) 7.6 ± 3.5 7.7 ± 3.1 6.1 ± 2.0 a,b 0.017
HDL composition
Cholesterol (%)1 17.1 ± 2.3 15.6 ± 3.0 a 17.3 ± 2.3 b 0.204
Trigycerides (%) 4.3 ± 1.7 6.7 ± 1.9 a 3.1 ± 1.0 a,b <0.001
Phospholipids (%) 33.5 ± 4.3 31.3 ± 3.3 a 32.8 ± 3.7 0.076
apoA-I (%) 31.9 ± 5.8 32.8 ± 6.3 34.3 ± 5.7 a,b 0.193
apoA-II (%) 13.2 ± 3.4 13.6 ± 2.6 12.5 ± 2.9 a,b 0.265
NEFA(mol/mol apoA-I) 1.1 ± 0.6 1.0 ± 0.6 1.0 ± 0.9 0.907
Ratio lipid/protein 1.20 ± 0.28 1.19 ± 0.27 1.16 ± 0.27 a,b 0.539
Ratio A-I/A-II 2.61 ± 0.92 2.54 ± 0.81 2.98 ± 1.12 a,b 0.112
Ratio chol/trigl 4.65 ± 2.19 2.57 ± 0.91 6.32 ± 2.68 a,b <0.001
PON1 activity 78.5 ± 25.5 82.6 ± 25.5 82.5 ± 23.1 0.152
(μmol/min/mL)
Lp-PLA2 activity(μmol/min/mL)
Total Lp-PLA2 20.1 ± 6.6 23.0 ± 7.2 a 19.1 ± 6.2 b 0.627
HDL-Lp-PLA2 6.8 ± 2.7 7.1 ± 3.5 6.2 ± 2.6 0.995
apoB-associated-Lp-PLA2 13.3 ± 4.8 15.9 ± 4.6 a 12.9 ± 3.3 b 0.539
% HDL-Lp-PLA2 33.9 ± 10.5 30.9 ± 11.4 a 32.4 ± 10.6 0.510
% apoB-associated-Lp-PLA2 66.1 ± 19.4 69.1 ± 21.2 a 67.6 ± 19.8 0.510
a, P < 0.05 vs phenotype A patients; b, P < 0.05 vs phenotype B patients.
1 Composition is expressed as the percentage of the mass of cholesterol, triglycerides, phospholipids, apoA-I and apoA-II.
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(variables with normal distribution) or the Mann–Whitney
U test (variables with non-normal distribution). Correla-
tions between parameters were analyzed using the Pear-
son R test for variables with normal distribution and the
Spearman test for variables with non-normal distribution.Figure 1 Lp-PLA2 activity. Enzymatic activity (A) and relative distribution
control subjects and patients with type 2 diabetes classified according theiData are expressed as mean ± SD. P < 0.05 was considered
significant.
Results
Table 1 shows anthropometrics, clinical characteristics and
lipid profile of patients and controls. One third (n = 45) ofbetween HDL and apoB-containing lipoproteins (B) of Lp-PLA2 in
r LDL subfraction phenotype. * indicates P < 0.05.
Table 3 Correlation analysis of LDL size with lipid profile,
modified LDLs, HDL composition and Lp-PLA2 activity in
patients with type 2 diabetes and control subjects
DM2 patients Control subjects
R P R P
HbA1c −0.160 0.071 −0.103 0.601
Insulin −0.076 0.418 0.008 0.937
Total cholesterol −0.185 0.035 −0.326 0.016
Triglycerides −0.553 < 0.001 −0.427 0.001
VLDLc −0.513 < 0.001 −0.423 0.001
LDLc −0.152 0.083 −0.333 0.014
HDLc 0.407 < 0.001 0.096 0.491
NEFA −0.226 0.004 −0.042 0.765
apoB −0.246 0.005 −0.458 < 0.001
apoA-I 0.264 0.002 −0.033 0.811
apoA-II −0.068 0.472 −0.099 0.476
Oxidized LDL −0.390 < 0.001 −0.472 < 0.001
Glycated LDL −0.273 0.003 −0.151 0.307
LDL(-) −0.020 0.828 0.030 0.849
Cholesterol in HDL 0.321 0.002 0.208 0.244
Trigycerides in HDL −0.398 < 0.001 −0.150 0.405
Phospholipids in HDL 0.437 < 0.001 0.067 0.712
apoA-I in HDL −0.205 0.047 0.086 0.635
apoA-II in HDL −0.169 0.103 −0.069 0.739
NEFA in HDL −0.010 0.925 0.086 0.635
PON1 0.016 0.867 0.024 0.872
Total Lp-PLA2 activity −0.123 0.172 0.025 0.862
HDL-Lp-PLA2 activity 0.030 0.745 0.061 0.680
% of HDL-Lp-PLA2 0.191 0.034 0.064 0.662
Bold type indicates the loss of statistical significance in the control group
compared to diabetic patients.
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size < 25.5 nm), in contrast to the control group in which
all subjects (n = 54) had phenotype A. Table 1 shows the
lipid profile of patients with type 2 diabetes and control
subjects. Both groups of patients had higher plasma levels
of triglyceride, VLDL cholesterol, apoB and NEFA and
lower concentration of HDL cholesterol and apoA-I than
control subjects. The lipid profile was worse in patients
with phenotype B. The differences observed in the two
groups of patients compared to controls were larger in
phenotype B patients, who also presented higher total chol-
esterol and LDL cholesterol than controls. The differences
between phenotype A and phenotype B patients included
higher total cholesterol, triglyceride, VLDLc, LDLc, apoB
and lower HDLc and apoA-I in patients with phenotype B
than in patients with phenotype A (Table 1).
Regarding modified LDLs, both groups of patients had
higher plasma concentration of oxLDL, glLDL and LDL(−)
than control subjects (Table 2). oxLDL and glLDL concen-
trations were higher in patients with phenotype B than in
patients with phenotype A. In contrast, the proportion of
LDL(−) was similar between both groups of patients.
The composition analysis of isolated HDL particles
showed that both groups of patients had an abnormal
composition compared to control samples (Table 2), with
some of these alterations being stronger in patients with
phenotype B. Differences between patients with phenotype
B and controls included a lower content of cholesterol
and apoA-I, and a higher content of triglycerides and
apoA-II. Similar differences were observed when controls
were compared with patients with phenotype A, except
that cholesterol content was similar in both groups. As a
consequence, the apoA-I/apoA-II ratio was lower and the
lipid/protein ratio was higher in HDL from both groups of
patients than in control subjects. Both ratios were similar
in patients with phenotype A and phenotype B. These ob-
servations suggest that HDL in both groups of patients
with diabetes has lower density and larger size than HDL
in control subjects. Regarding PON1 activity, no differ-
ence was observed.
Total and apoB-associated Lp-PLA2 activity was higher
in patients with phenotype B than in control subjects and
in patients with phenotype A, and was similar in the two
latter groups (Table 2, Figure 1A). No statistical difference
was observed in the HDL-associated Lp-PLA2 activity.
Consequently, the distribution of Lp-PLA2 between HDL
and apoB-containing lipoproteins (Table 2, Figure 1B) was
different between patients with phenotype A and those
with phenotype B. The latter had lower proportion of Lp-
PLA2 in HDL and higher proportion in apoB-containing
lipoproteins than in patients with phenotype A.
Covariance analysis (ANCOVA) showed that the differ-
ences seen in apoB and glLDL disappeared after adjusting
for TG. Differences observed in LDL(−) and oxLDL losttheir significance after adjusting for HbA1c and TG (data
not shown). These associations are expected and under-
line the known relation of LDL(−) and oxLDL with the
presence of diabetes and hypertriglyceridemia, and of
apoB and glLDL with hypertriglyceridemia. Table 3 shows
the correlation analysis of LDL size with lipid profile,
modified LDLs, HDL composition and Lp-PLA2 activity.
In diabetic patients, significant correlations with the pa-
rameters of lipid profile were similar to those previously
reported: LDL size correlated negatively with triglycerides,
cholesterol, VLDLc, apoB and NEFA, and positively with
HDLc and apoA-I. LDL size also correlated negatively with
oxLDL and glLDL. Regarding HDL composition, LDL size
correlated positively with the content of phospholipids,
cholesterol and Lp-PLA2, and negatively with the content
of triglycerides and apoA-I. The correlation analysis of the
control group showed some differences compared to dia-
betic patients. Most of correlations observed between LDL
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except the positive correlation with HDLc and the negative
correlation with plasma NEFA, which were lost in the con-
trol group. The negative correlation with glLDL as well as
the correlations with some HDL components also were
lost in control subjects. These observations suggest that
the influence of LDL size on HDL composition and glLDL
is stronger in diabetic patients than in control subjects.
Discussion
Several authors have reported differences in the qualita-
tive characteristics of HDL and LDL between diabetic
and healthy subjects. However, most of these studies an-
alyzed separately LDL and HDL and, despite the high
prevalence of LDL phenotype B in type 2 diabetes, these
characteristics have not been usually compared classify-
ing diabetic subjects according to their LDL subfraction
phenotype. Regarding Lp-PLA2, its distribution has been
analyzed comparing LDL phenotypes only in one study
[18], but not in patients with diabetes. The novelty of
our study is to analyze simultaneously oxLDL, glLDL,
LDL(−), HDL composition and distribution of Lp-PLA2
in patients with type 2 diabetes classified according to
LDL phenotype.
Results in the current study concur with previous find-
ings reporting that oxLDL, glLDL and LDL(−) are increased
in diabetes [7,19,20]. Our data show that oxLDL and glLDL
are increased in patients with phenotype A compared to
control subjects, but this situation is more marked in pa-
tients with phenotype B. The high concentration of oxLDL
and glLDL observed in patients with phenotype B could be
attributed to several mechanisms. It is known that sdLDL
has an impaired plasma clearance, which could lead to in-
creased residence time in blood and favor further modifica-
tions. This could be related to the high susceptibility to
oxidation and to non-enzymatic glycosylation that has been
demonstrated both “in vitro” and “in vivo” in sdLDL parti-
cles [5]. In this context, it is worthy mentioning the work
by Younis et al., who recently reported that sdLDL concen-
tration is an even stronger determinant of LDL glycation
than hyperglycemia [21]. However, differences in oxLDL
and glLDL between patients with phenotype A and control
subjects still remained significant. Therefore, factors other
than LDL size could account for these differences. First,
hyperglycemia and increased oxidative stress, which are
hallmarks of diabetes, affect circulating LDL, even in pa-
tients with phenotype A. Another possible explanation is
related to the altered composition of HDL observed in both
groups of patients with type 2 diabetes. Our results indicate
that HDL composition was abnormal in both groups of pa-
tients, although alterations were stronger in phenotype B
patients. These differences included apoA-I/apoA-II and
lipid/protein ratios. A decrease of apoA-I in HDL with a
concomitant increase of apoA-II produces particles withlower antioxidant capacity [15]. Likewise, higher lipid/pro-
tein ratio suggests an impairment of the antioxidant prop-
erties of HDL, since the HDL3 subfraction (with lower
lipid/protein ratio) has a stronger antioxidant capacity
than the HDL2 subfraction (with higher lipid/protein ra-
tio) [22].
The alterations in the composition of HDL from patients
with diabetes also point to a decreased ability to promote
reverse cholesterol transport. An increased triglyceride and
decreased cholesterol content in HDL has been related
with impaired cholesterol efflux from adipose and hepatic
cells [23]. This alteration was present in HDL isolated from
our patients and could be indicative of such impairment.
This would be pronounced in diabetic subjects with
phenotype B in which the ratio cholesterol/triglyceride in
HDL is 2.5-fold lower than in control subjects.
Although the concentration of oxLDL and glLDL was in-
creased in patients with phenotype B, the relative content
of LDL(−) was not affected by the presence of sdLDL parti-
cles, because there was no difference between phenotype A
and phenotype B patients. This observation suggests that
although oxidation and glycosylation could be partially in-
volved in the generation of LDL(−), these would not be the
major mechanisms in diabetes. Other mechanism involved
in the formation of LDL(−) in diabetes is NEFA-loading.
[14]. As a consequence, the increased plasma level of NEFA
is probably a major cause of increased LDL(−) in diabetes.
The role of Lp-PLA2 in atherogenesis is controversial.
Lp-PLA2 is thought to play a role in the prevention of oxi-
dative modifications [24], but it has been positively associ-
ated to coronary heart disease. Most epidemiological
studies have found a relationship between Lp-PLA2 and
coronary events or ischemic stroke [25]. However, Lp-
PLA2 shows a strong association with total and LDL chol-
esterol levels, and there is no definitive agreement regard-
ing whether this biomarker is independent from LDL
concentration [26]. Few studies have been performed in
patients with type 2 diabetes and results are controversial.
Nelson et al. recently reported that Lp-PLA2 predicts fu-
ture risk of incident type 2 diabetes [27], but the Rotter-
dam Study did not find an association between the
presence of diabetes and total Lp-PLA2 activity [28]. Re-
garding the association of Lp-PLA2 with cardiovascular
disease, Hatoum et al. described that Lp-PLA2 activity
was associated with incident coronary heart disease in pa-
tients with type 2 diabetes [29], but Nelson et al. reported
that the Lp-PLA2 activity did not explain the excess of
cardiovascular risk in diabetes [30]. To further complicate
the matter, Kizer et al. found divergent associations be-
tween Lp-PLA2 activity and Lp-PLA2 mass and the risk
of cardiovascular disease in a population with high preva-
lence of diabetes [31]. These authors suggest that a pos-
sible explanation for these paradoxical findings could be
related to the distribution of Lp-PLA2 among lipoprotein
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the distribution of Lp-PLA2 between lipoproteins in dia-
betes. Kujiraoka et al. reported that, although no difference
was observed in total Lp-PLA2 activity between patients
with diabetes and control subjects, Lp-PLA2 distribution
was altered in the former, with a lower proportion bound to
HDL [32]. In a recent study, Mitsutake et al. obtained simi-
lar results in diabetic patients and also found that Lp-PLA2
in HDL was lower in subjects with increased coronary artery
calcification [33]. Finally, Onat et al., which measured Lp-
PLA2 mass, agreed with these authors and also found de-
creased content of this enzyme in HDL from diabetic pa-
tients [34]. However, none of these studies took into
account the presence of phenotype B. Our data indicate that
increased total Lp-PLA2 activity and abnormal distribution
of Lp-PLA2 is strongly dependent on the presence of LDL
subfraction phenotype B. The higher content of Lp-PLA2 in
apoB-containing lipoproteins from patients with phenotype
B is probably due to the higher affinity of this enzyme for
the binding to sdLDL particles than to large, buoyant LDL
particles [18]. The observation that Lp-PLA2 has a lower
content in HDL from patients with phenotype B than from
those with phenotype A concurs with the concept that this
enzyme has an antioxidant role when is bound to HDL [35].
This could account for the increased concentration of
oxLDL in diabetic patients with phenotype B.
Conclusions
Our data agree with previous reports of alterations in the
qualitative characteristics of LDL and HDL in patients
with type 2 diabetes and demonstrate that some, but not
all, of these abnormalities, are closely related to the pres-
ence of LDL subfraction phenotype B. Specifically, a high
concentration of oxLDL and glLDL and a higher content
of Lp-PLA2 in apoB-containing lipoproteins are favored
by the presence of sdLDL particles. In addition, alterations
observed in the composition of HDL from patients with
phenotype B were stronger than in patients with pheno-
type A. The relevance of these results resides in the high
prevalence of phenotype B among patients with poorly-
controlled type 2 diabetes. Therapies focused on changing
the LDL subfraction phenotype, such as fibrates [36] or
glycemic optimization [37], would improve some qualita-
tive pro-atherogenic characteristics of LDL and help to
lower the increase in CVR present in type 2 diabetes.
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